Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 2015. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), and connected persons, in accordance with DTR 3.1.4 R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details specific share acquisitions on January 9, 2015, executed at a price of 1,427.64 pence per Ordinary share. These transactions resulted from the re-investment of dividends on shares held within an Individual Savings Account (ISA). The specific acquisitions were:
- Sir Andrew Witty (Director): 110 Ordinary shares
- Mr D S Redfern (Director/PDMR): 21 Ordinary shares
- Mrs V A Whyte (Director/PDMR): 18 Ordinary shares
- Lady C Witty (Connected Person): 21 Ordinary shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the statutory notification of the aforementioned share transactions.
Investor Verification Checklist
- Verify the share price of 1,427.64 pence per Ordinary share on January 9, 2015.
- Confirm the total number of shares acquired by directors and connected persons via dividend re-investment.
- Review the full list of directors and PDMRs to ensure all required disclosures for the period are complete.